The Eye Care Blog

Global bio-nanotech company pSivida Limited (NASDAQ:PSDV) (ASX:PSD) (Xetra:PSI) today announced the initiation of a Phase II clinical trial of Mifepristone (otherwise known as RU486) as an eye drop treatment for steroid associated elevated intraocular pressure (IOP).

The investigator-sponsored trial will involve up to 45 patients in the United States. pSivida will be supplying clinical trial material for this study and has filed a patent application on this product class.

Elevated IOP may occur in patients receiving steroidal treatment for chronic eye diseases. The trial will investigate the use of Mifepristone as a means to prevent elevation of IOP from intraocular steroid exposure. Mifepristone is a steroid receptor antagonist ("steroid blocker") already approved by the FDA. This study represents a potential new use of an existing drug, made possible by a new delivery system.

Link

You may also like to read

• Lumigan, Allergan's Intraocular Pressure Drug, Received FDA Approval
• Alcon Gets FDA Approval for Travatan-Z Which Reduce Elevated Intraocular Pressure
• Combination Antibiotic-Steroid for Ocular Inflammation Filed for FDA Approval
• Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular Degeneration
• Novagali eye Treatment for Vernal Keratoconjunctivitis (VKC) Successful in Phase III Trial
• Timely Treatment Can Help To Cure Glaucoma
• Can-Fite Begins Phase II Trials for Treatment of Symptoms of Keratitis Sicca (Dry-Eye Syndrome)
• India and Australia Come Together For The Clinical Trial Of Selenium-Coated Contact Lenses
• Glaucoma Can Be Cured By Motogenol - A Natural Formula
• Axial Myopia May be Treated By Hydrogel

This entry was posted on Wednesday, September 27th, 2006 at 10:13 am. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.